Highest-materiality recent filing
Nomad Power increases Voyager fleet energy storage by up to 56% across all models
Voyager Eagle and Falcon storage increased to 2.025 MWh each, up 56% from 1.3 MWh.
Lixte completes merger with NOMAD, changes name to Nomad Power Solutions, ticker to NMAD
Merger closed July 1, 2026; NOMAD becomes wholly owned subsidiary of Lixte.
Lixte issues $6.5M secured note to NOMAD for pending merger
Issued $6.5M secured promissory note to NOMAD in connection with pending merger.
Lixte Biotechnology to acquire NOMAD Transportable Power Systems, pivoting to energy storage
Consideration: up to 50,500 Series D Convertible Preferred shares ($1,000/sh, convertible at $1.00) plus up to 3M common shares.
Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants
Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.
Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board
Company will seek strategic acquisition partner for clinical-stage pharma/med-tech operations.
CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.
Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026
CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.
Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake
Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
LIXTE appoints Sidney Braun CEO of Liora; GBP 50K signing bonus, GBP 25K monthly retainer
Braun becomes CEO of Liora Technologies Europe Ltd., effective Feb 13, 2026.
Lixte exchanges 2,700 Series C preferred for 700K common shares and 20% of Liora subsidiary
Orbit Capital Inc. exchanged 2,700 Series C Preferred shares for 700,000 Lixte common shares and 200 ordinary shares of Liora (20% of Liora).
Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026
Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement
Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).
Lixte shareholders elect all five directors, ratify auditor, approve stock plan increase
All five director nominees elected: Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, Guy Primus.
Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
LIXTE makes $2.6M initial cryptocurrency purchase to diversify treasury
Purchased 10.5 Bitcoin and 300 Ethereum for total of $2.6 million.
Lixte appoints new CFO, two board members; relocates HQ to Boca Raton
Rene Bernards, Regina Brown, Bas van der Baan resigned from Board; CFO Robert Weingarten resigned; all departures amicable.
LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance
Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.
Board approved allocating up to 25% of corporate treasury to cryptocurrencies including Bitcoin.
Lixte appoints two new independent directors; CMO resigns effective July 31
Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.
LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise
Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers
Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.
Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants
Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.
Lixte closes $5.0M private placement of common stock, preferred and warrants
Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.
Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3
Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
Lixte receives conversion notice for 350,000 Series A Preferred shares into 72,917 common shares
Notice received May 16, 2025 for 350,000 Series A Convertible Preferred shares.
Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance
Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.
Lixte launches pre-clinical study of LB-100 to target pre-cancerous cells with NKI
New pre-clinical study tests if initiated cells with mutant RAS oncogene can be eliminated by LB-100.
LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed
First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.
Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study
Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.
Enzyme discovered that converts LB-100 to active metabolite endothall, published in BioXriv and Int'l J. Pharmaceutics.
Lixte terminates at-the-market equity facility with WallachBeth Capital; effective March 18, 2025
Notice of termination of Sales Agreement with WallachBeth Capital LLC given on March 7, 2025.
Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.
Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting
Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.
Lixte Biotechnology raises $1.05M in registered direct offering and private placement
Issued 434,784 shares at $2.415/share and warrants for 434,784 shares at $2.29/share.
Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital
Entered ATM sales agreement to sell up to $1.7M of common stock.
Lixte Biotechnology VP and COO Eric Forman resigns effective Dec 31, 2024
Eric Forman resigned as VP and COO of Lixte Biotechnology Holdings, effective December 31, 2024.
Lixte Biotechnology announces annual meeting results; all director nominees elected
All five director nominees (Forman, Yen, Brown, Bernards, van der Baan) elected with >653K votes for each.
Lixte pauses NKI/Oncode collaboration until Phase 1b trial starts; budget cut to €100K
Amendment 3 pauses research activities under the development collaboration with NKI and Oncode Institute.
Lixte Biotechnology gets Nasdaq extension to Feb 18, 2025 to meet equity requirement
Nasdaq notified non-compliance with $2.5M minimum stockholders' equity requirement.
LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies
U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.
Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support
Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.
Lixte Biotechnology receives Nasdaq deficiency notice for stockholders' equity requirement
Received Notice from Nasdaq on August 19, 2024 for non-compliance with Listing Rule 5550(b)(1) requiring minimum $2,500,000 stockholders' equity.
LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination
New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.
Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites
Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.
Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.
Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI
Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.
Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.
Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024
Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.
Lixte Biotechnology notifies CMO James Miser of non-renewal; employment ends July 31, 2024
Dr. James Miser's employment agreement not renewed; CMO role ends July 31, 2024.
On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.
Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer
effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer.
Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.
Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.
Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.
Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.
On May 9, 2022, Philip Palmedo informed the Company that he did not intend to stand for reelection at the next Annual Meeting of Stockholders of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material